(Q50148222)

English

Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial.

scientific article published on 2 November 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 February 2018

http://europepmc.org/abstract/MED/29104158

Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial. (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 February 2018

http://europepmc.org/abstract/MED/29104158

type 2 diabetes

1 reference

based on heuristic

inferred from title

Matias Trillini

object named as

Matias Trillini

2

0 references

Giuseppe Remuzzi

object named as

Giuseppe Remuzzi

17

0 references

Piero Ruggenenti

19

object named as

Piero Ruggenenti

1 reference

Europe PubMed Central

PubMed publication ID

26 February 2018

http://europepmc.org/abstract/MED/29104158

7

object named as

Annalisa Perna

1 reference

Europe PubMed Central

PubMed publication ID

26 February 2018

http://europepmc.org/abstract/MED/29104158

Martin H de Borst

object named as

Martin de Borst

18

0 references

9

object named as

Olimpia Diadei

1 reference

Europe PubMed Central

PubMed publication ID

26 February 2018

http://europepmc.org/abstract/MED/29104158

6

object named as

Manuela Abbate

1 reference

Europe PubMed Central

PubMed publication ID

26 February 2018

http://europepmc.org/abstract/MED/29104158

10

object named as

Nadia Rubis

1 reference

Europe PubMed Central

PubMed publication ID

26 February 2018

http://europepmc.org/abstract/MED/29104158

11

object named as

Flavio Gaspari

1 reference

Europe PubMed Central

PubMed publication ID

26 February 2018

http://europepmc.org/abstract/MED/29104158

Roberto Trevisan

16

object named as

Roberto Trevisan

1 reference

Europe PubMed Central

PubMed publication ID

26 February 2018

http://europepmc.org/abstract/MED/29104158

Aneliya I Parvanova

1

object named as

Aneliya Parvanova

1 reference

Europe PubMed Central

PubMed publication ID

26 February 2018

http://europepmc.org/abstract/MED/29104158

Fabiola Carrara

12

object named as

Fabiola Carrara

1 reference

Europe PubMed Central

PubMed publication ID

26 February 2018

http://europepmc.org/abstract/MED/29104158

13

object named as

Nadia Stucchi

1 reference

Europe PubMed Central

PubMed publication ID

26 February 2018

http://europepmc.org/abstract/MED/29104158

Ilian Petrov Iliev

4

object named as

Ilian Petrov Iliev

1 reference

Europe PubMed Central

PubMed publication ID

26 February 2018

http://europepmc.org/abstract/MED/29104158

Barbara Ruggiero

5

object named as

Barbara Ruggiero

1 reference

Europe PubMed Central

PubMed publication ID

26 February 2018

http://europepmc.org/abstract/MED/29104158

Francesco Peraro

8

object named as

Francesco Peraro

1 reference

Europe PubMed Central

PubMed publication ID

26 February 2018

http://europepmc.org/abstract/MED/29104158

15

object named as

Antonio C Bossi

1 reference

Europe PubMed Central

PubMed publication ID

26 February 2018

http://europepmc.org/abstract/MED/29104158

author name string

Manuel A Podestà

3

1 reference

Europe PubMed Central

PubMed publication ID

26 February 2018

http://europepmc.org/abstract/MED/29104158

Antonio Belviso

14

1 reference

Europe PubMed Central

PubMed publication ID

26 February 2018

http://europepmc.org/abstract/MED/29104158

PROCEED Study Organization and the Scientific Writing Academy (SWA) 2016

20

1 reference

Europe PubMed Central

PubMed publication ID

26 February 2018

http://europepmc.org/abstract/MED/29104158

publication date

2 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 February 2018

http://europepmc.org/abstract/MED/29104158

The Lancet: Diabetes & Endocrinology

1 reference

Europe PubMed Central

PubMed publication ID

26 February 2018

http://europepmc.org/abstract/MED/29104158

6

1 reference

Europe PubMed Central

PubMed publication ID

26 February 2018

http://europepmc.org/abstract/MED/29104158

1

1 reference

Europe PubMed Central

PubMed publication ID

26 February 2018

http://europepmc.org/abstract/MED/29104158

27-40

1 reference

Europe PubMed Central

PubMed publication ID

26 February 2018

http://europepmc.org/abstract/MED/29104158

Temporal trends in the prevalence of diabetic kidney disease in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930359-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms and treatment of CKD.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930359-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical practice. Nephropathy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930359-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The RAAS in the pathogenesis and treatment of diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930359-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Retarding progression of chronic renal disease: the neglected issue of residual proteinuria

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930359-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930359-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930359-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930359-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930359-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Possible renoprotection by vitamin D in chronic renal disease: beyond mineral metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930359-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Vitamin D analogue therapy, cardiovascular risk and kidney function in people with Type 1 diabetes mellitus and diabetic nephropathy: a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930359-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930359-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Benefits of and barriers to dietary sodium adherence

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930359-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Sodium intake, ACE inhibition, and progression to ESRD.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930359-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Global, regional and national sodium intakes in 1990 and 2010: a systematic analysis of 24 h urinary sodium excretion and dietary surveys worldwide

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930359-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Renal and Systemic Effects of Calorie Restriction in Patients With Type 2 Diabetes With Abdominal Obesity: A Randomized Controlled Trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930359-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Glomerular hyperfiltration and renal disease progression in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930359-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of Vitamin D Receptor Activation and Dietary Sodium Restriction on Residual Albuminuria in CKD: The ViRTUE-CKD Trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930359-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Benefits of dietary sodium restriction in the management of chronic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930359-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Suppression of renin-angiotensin gene expression in the kidney by paricalcitol

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930359-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Active vitamin D treatment for reduction of residual proteinuria: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930359-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930359-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Antifibrotic, nephroprotective effects of paricalcitol versus calcitriol on top of ACE-inhibitor therapy in the COL4A3 knockout mouse model for progressive renal fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930359-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A double-blind, randomized, placebo-controlled trial of combined calcitriol and ergocalciferol versus ergocalciferol alone in chronic kidney disease with proteinuria

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930359-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of a Single Baseline Versus Multi-Year 24-Hour Urine Collections for Estimation of Long-Term Sodium Intake and Associated Cardiovascular and Renal Risk.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930359-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S2213-8587(17)30359-5

1 reference

Europe PubMed Central

PubMed publication ID

26 February 2018

http://europepmc.org/abstract/MED/29104158

release_2o6zmzv65rfjvjspdwcgjofo5u

1 reference

https://api.fatcat.wiki/v0/release/2o6zmzv65rfjvjspdwcgjofo5u

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 February 2018

http://europepmc.org/abstract/MED/29104158

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50148222&oldid=1840539691"